areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com
Preclinical Validation in Freely Moving Large Animals In a chronic study of three sheep, the SNS demonstrated stable performance across core functions: Neural-state decoding. Machine-learning classifiers distinguished movement from stillness with...
sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone. For more information please visit, www.sepsis.com
Sapio Sciences, the science-awareTM AI lab informatics platform, announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the Institute’s ambitious lab transformation program. The...
Medra, the company developing the first platform for Physical AI Scientists, announced a $52 million Series A financing led by Human Capital, with participation from existing investors Lux Capital, Neo, and NFDG, alongside new investors Catalio...
Kingdom, in Japan and Europe (27 countries of the European Union as well as Iceland, Liechtenstein and Norway). For more information please visit, www.servier.com
global expansion and reinforces its mission to bring real-time kidney data into clinical decision-making. By transforming urine output into a continuously measured and analysed digital parameter, FIZE enables clinicians to better assess kidney...
Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA® is helping to establish a new era of endoscopic bariatric treatment –...
Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea. “Today’s approval lays a solid foundation for Celltrion’s expansion...
denosumab-containing medicinal products Hypercalcaemia in paediatric patients These highlights do not include all the information needed to use OBODENCE safely and effectively. Refer to the Summary of Product Characteristics for OBODENCE’s full...
and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that the company will present new data related to ELZONRIS®...
entire treatment journey. The injection time for each LEQEMBI IQLIK autoinjector takes approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion...
VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), announced the successful closing of its $23 million Series B financing led by S3 Ventures, with support from Intuitive Ventures, and a strategic...
injection once every three months. REDEMPLO utilizes the proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform and is Arrowhead’s first FDA-approved medicine, marking a major milestone for the company as it transitions into...
Emulate Brain-Chip R1. This first-in-class isogenic model of the neurovascular unit offers researchers a powerful new platform for studying drug transport across the blood-brain barrier (BBB) and investigating mechanisms of neuroinflammation. The...
clinical and preclinical research evaluating Modeyso™ (dordaviprone), as well as new preclinical data featuring JZP3507 (formerly ONC206) in central nervous system (CNS) tumors, reflecting Jazz's growing impact and innovation in neuro-oncology. Key...
What are the possible side effects of TREMFYA®? TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?" The most common side effects of TREMFYA® include: respiratory tract infections,...
the U.S. market and makes the only oral testosterone replacement therapy option available under a softgel capsule dosage form in Canada. Building on Marius’s earlier submission to Health Canada in July 2024, the company is now poised to provide...
in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company...
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology,...
